HLA-A*02:01

1 EU-approved indication of 1 drug needs a HLA-A*02:01 result, in 1 tumour type, most of them in uveal melanoma.

Approved indications1

DrugBiomarker requirementRegimenSettingConditions
Uveal melanoma1
Tebentafusp
Kimmtrak
Monotherapy
Any line
advanced
None

HLA-A*02:01 by tumour

Label wording1

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Tebentafusp (Kimmtrak)
    KIMMTRAK is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.